June 11, 2024 June 11, 2024Categories Active Clinical TrialsNow Enrolling: myeloMATCH Treatment Trial MM1OA-EA02 for Older Patients with Newly Diagnosed FLT3-Mutated Acute Myeloid LeukemiaThis phase 2 study is testing two variations of the triplet combination of azacitidine, venetoclax, and gilteritinib compared to standard therapy
September 30, 2021 September 30, 2021Categories Active Clinical TrialsTrial Spotlight: Selina Luger on the PrE0905 Study for FLT3 Mutated Acute Myeloid LeukemiaThis phase II trial is exploring the targeted cancer therapy gilteritinib, a tyrosine kinase inhibitor that kills leukemia cells by binding to the mutant FLT3 protein and blocking its activity
June 10, 2020 June 10, 2020Categories Active Clinical TrialsNow Enrolling: PrE0905 for Acute Myeloid LeukemiaThis phase II study is exploring the potent FLT3 inhibitor gilteritinib